Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 1.00 |
| ▸ | MMP2 | P08253 | 3/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | FNTA | P49354 | 1/20 | 0.78 |
| ▸ | FNTB | P49356 | 1/20 | 0.78 |
| ▸ | MEN1 | O00255 | 12/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 12/20 | 0.77 |
| ▸ | RECQL | P46063 | 8/20 | 0.77 |
| ▸ | MAPT | P10636 | 7/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.77 |
| ▸ | USP2 | O75604 | 5/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.77 |
| ▸ | TP53 | P04637 | 3/20 | 0.77 |
| ▸ | HBB | P68871 | 2/20 | 0.77 |
| ▸ | BLM | P54132 | 10/20 | 0.67 |
| ▸ | THRB | P10828 | 10/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.67 |
| ▸ | CASP1 | P29466 | 2/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.67 |
| ▸ | BRCA1 | P38398 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aclarubicin SCHEMBL2804048 | 1.00 | PTGS1 (1.00) | PTGS1MMP2HTR2BFNTAFNTB | |
| Aclarubicin SCHEMBL29390785 | 1.00 | PTGS1 (1.00) | PTGS1MMP2HTR2BFNTAFNTB | |
| Aclarubicin SCHEMBL31238004 | 1.00 | PTGS1 (1.00) | PTGS1MMP2HTR2BFNTAFNTB | |
| Aclarubicin SCHEMBL1649619 | 1.00 | PTGS1 (1.00) | PTGS1MMP2HTR2BFNTAFNTB | |
| Aclarubicin SCHEMBL10061856 | 1.00 | PTGS1 (1.00) | PTGS1MMP2HTR2BFNTAFNTB | |
| Aclarubicin SCHEMBL10201119 | 1.00 | PTGS1 (1.00) | PTGS1MMP2HTR2BFNTAFNTB | |
| Aclarubicin SCHEMBL10079204 | 1.00 | PTGS1 (1.00) | PTGS1MMP2HTR2BFNTAFNTB | |
| Aclarubicin SCHEMBL17035568 | 1.00 | PTGS1 (1.00) | PTGS1MMP2HTR2BFNTAFNTB | |
| Aclarubicin SCHEMBL6255351 | 1.00 | PTGS1 (1.00) | PTGS1MMP2HTR2BFNTAFNTB | |
| Aclarubicin SCHEMBL31277372 | 1.00 | PTGS1 (1.00) | PTGS1MMP2HTR2BFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 29801 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137671-A1 | PDK4 as a Cell-Aging Intervention Target and Its Use in Chemotherapy and Anticancer | SHANGHAI INST OF NUTRITION AND HEALTH CHINESE ACADEMY OF SCIENCES (CN) | 2026-05-21 | — | — | US | claimed |
| US-20260137686-A1 | SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2026-05-21 | — | — | US | claimed |
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SYSTIMMUNE INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137685-A1 | SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2026-05-21 | — | — | US | claimed |
| WO-2026103267-A1 | USE OF SESQUITERPENOIDS IN RELIEVING NAUSEA AND VOMITING | 辽宁新中现代医药有限公司 | 2026-05-21 | — | — | WO | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| EP-4727589-A1 | PROTAMINE-COATED NUCLEIC ACID/THERAPEUTIC AGENT COMPLEXES, AND USES THEREOF | The Regents of the University of California (US) | 2026-04-22 | — | — | EP | claimed |
| US-20260085061-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2026-03-26 | — | — | US | claimed |
| US-12576077-B2 | Composition for preventing, alleviating or treating cancer | CKP THERAPEUTICS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4691495-A1 | USE OF DRUG COMBINATION CONTAINING ANTI-CD20 ANTIBODY-DRUG CONJUGATE IN PREPARATION OF DRUG FOR TREATING NHL | Zhejiang Teruisi Pharmaceutical Inc. (CN) | 2026-02-11 | — | — | EP | claimed |
| EP-0547191-B1 | PARTICULATE VECTOR HAVING SELECTIVE TROPISM, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION | BIOVECTOR THERAPEUTICS SA (FR) | 1996-12-04 | — | — | EP | claimed |
| EP-0393575-B1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | SEARLE & CO (US) | 1994-03-16 | — | — | EP | claimed |
| EP-0359347-B1 | COVALENTLY-LINKED COMPLEXES AND METHODS FOR ENHANCED CYTOTOXICITY AND IMAGING | NEORX CORPORATION (US) | 1992-12-23 | — | — | EP | claimed |
| EP-0132105-B1 | OILY COMPOSITION OF ACLARUBICIN OR HYDROCHLORIDE THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1990-10-31 | — | — | EP | claimed |
| EP-0393575-A1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | G.D. Searle & Co. (US) | 1990-10-24 | — | — | EP | claimed |
| EP-0392487-A2 | Stabilized composition of anthracyclines | Takeda Chemical Industries, Ltd. (JP) | 1990-10-17 | — | — | EP | claimed |
| EP-0359347-A2 | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging | NEORX CORPORATION (US) | 1990-03-21 | — | — | EP | claimed |
| US-4863902-A | EPIDERMAL GROWTH FACTOR OR PLATELET DERIVED GROWTH FACTOR | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1989-09-05 | — | — | US | claimed |
| US-4772590-A | Oily composition of aclarubicin or hydrochloride thereof | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1988-09-20 | — | — | US | claimed |
| EP-0132105-A2 | Oily composition of aclarubicin or hydrochloride thereof | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1985-01-23 | — | — | EP | claimed |